Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00651417
Other study ID # Germanium
Secondary ID
Status Recruiting
Phase Phase 2
First received March 31, 2008
Last updated June 21, 2011
Start date April 2005
Est. completion date December 2012

Study information

Verified date June 2011
Source Arizona Oncology Services
Contact Terry Thomas, MS, CCRC
Phone 602-240-3383
Email theresa@azoncology.com
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

Participants will be diagnosed with localized prostate or breast cancer and be scheduled to undergo external beam radiation therapy. Participants will either receive a placebo or organic germanium to be taken 5 times a day starting the day of their first radiation and continuing through the 1 month follow-up visit. Weekly Quality of life forms will be completed through the one month follow up visit and then at the 3 month follow up visit. Labs will be done prior to the start of treatment, at the end of treatment and at the one and three month follow-up visits.


Description:

With the increasing public use of complementary medicines, most researchers agree that there is a compelling need to study the safety and efficacy of these agents in humans by means of appropriately designed double-blind, placebo controlled clinical trials. With fatigue affecting 96% of the cancer patient population and little more than life style alterations offered as an intervention, the need to evaluate putative and innovative approaches for fatigue is a high priority. The NIH released a "State of the Science" statement in 2002 which concluded that fatigue is a serious cause of morbidity, being the most prevalent symptom experienced by cancer patients. This expert panel also concluded that the major barrier to effective management of fatigue includes a lack of awareness of this fact, the lack of knowledge of the causes of fatigue, and the lack of proven methods to treat fatigue. Presently, clinical trials evaluating intervention for cancer fatigue are lacking.

Organic germanium literature states that it may be an effective agent for combating fatigue with virtually no toxicities. Since virtually all cancer patients receiving radiation therapy experience fatigue, the use of this drug should be evaluated as an intervention for non-anemic fatigue in breast and prostate cancer patients undergoing a definitive course of radiation therapy. We intend to test whether organic germanium is able to reduce the fatigue experienced by patients undergoing radiation therapy and if this reduction in fatigue correlates to an improvement in quality of life for these patients. Changes in the patients' mood will also be evaluated. We will also collect information on the toxicity profile of Organic germanium and try to determine when the peak fatigue time occurs and possibly when they recover. This information will be utilized to see if a larger study is warranted.

2.0 OBJECTIVES 2.1 Primary: To determine if Organic germanium is effective in decreasing severity of fatigue in patients undergoing definitive radiation therapy for prostate or breast cancer at the one month follow-up visit.

2.2 Secondary 2.2.1 To compare changes in patients' moods between Organic germanium versus placebo at the one month follow-up visit 2.2.2 To compare the duration of fatigue between organic germanium and placebo 2.2.3 To further evaluate the toxicity profile of organic germanium using the CTCAE version 3 scale.

2.2.4 To determine the Peak time of fatigue in patients receiving external beam radiotherapy or high dose rate brachytherapy for breast or prostate cancer.

2.2.5 To determine the tolerability of 5 tablets per day as the dosing schema. 2.2.6 To determine when the patients recover from their radiation induced fatigue


Recruitment information / eligibility

Status Recruiting
Enrollment 101
Est. completion date December 2012
Est. primary completion date December 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Histologically-confirmed diagnosis of breast (females only) or prostate cancer

2. Zubrod performance status of 0-1.

3. Patients must be = 18 years of age.

4. Scheduled to undergo definitive radiation therapy (either brachytherapy or external beam)

5. Patients may have received or be receiving hormonal therapy. Prior chemotherapy is allowed as long as the patient has recovered from any toxicity. Planned future chemotherapy is also allowed after the one month evaluation.

6. Hgb = 10 g/dl, BUN < 25 mg and creatinine < 1.5 mg

7. Patient must be able to comply with treatment regimen.

8. Patient must complete the pre-treatment quality of life questionnaires.

9. Women of childbearing potential must have a pre-treatment pregnancy test; women of childbearing potential and men able to father children must use non-hormonal-based birth control while on study.

10. Patients must sign study-specific informed consent prior to study entry.

Exclusion Criteria:

1. Known allergies or reactions to Organic germanium

2. Prior irradiation other than basal cell cancer of skin

3. Current or past history of metastasis

4. Current history of uncontrolled hypertension, insulin dependent or uncontrolled diabetes, cardiovascular disease unless controlled and stable for 6 months or more, bleeding disorders, or autoimmune disorders such as fibromyalgia, chronic fatigue syndrome or lupus

5. Current use of corticosteroids or erythropoietin

6. Patients currently taking Organic germanium, or who have taken Organic germanium within the past three months

7. Pregnant or lactating women, as treatment involves unforeseeable risks to the participant and to the embryo or fetus

8. Patients who are unable to complete quality of life questionnaires

9. Male breast cancer patients

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Organic Germanium
Oral organic Germaium tablets on the tongue 3 to 5 times per day as tolerated
Placebo
Placebo tablets orally 3 - 5 times per day as tolerated

Locations

Country Name City State
United States Arizona Oncology Services Phoenix Arizona

Sponsors (1)

Lead Sponsor Collaborator
Arizona Oncology Services

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To determine if Organic germanium is effective in decreasing severity of fatigue in patients undergoing definitive radiation therapy for prostate or breast cancer at the one month follow-up visit. One month pst treatment No
Secondary To compare changes in patients' moods between Organic germanium versus placebo at the one month follow-up visit One month follow up No
Secondary To compare the duration of fatigue between organic germanium and placebo One month follow up No
Secondary To further evaluate the toxicity profile of organic germanium using the CTCAE version 3 scale. one month follow up Yes
Secondary To determine the Peak time of fatigue in patients receiving external beam radiotherapy or high dose rate brachytherapy for breast or prostate cancer. one month follow up No
Secondary To determine when the patients recover from their radiation induced fatigue 3 month follow-up No
See also
  Status Clinical Trial Phase
Completed NCT03996005 - MRI- Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer N/A
Withdrawn NCT02159690 - A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy Phase 2
Completed NCT00196781 - Treatment Decision Making in Early-Stage Prostate Cancer Phase 3
Recruiting NCT03821246 - Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy Phase 2
Active, not recruiting NCT03814252 - Prospective Clinical Safety and Efficacy Study of Lesion-targeted MRI-TULSA for Localized Prostate Cancer N/A
Completed NCT01931046 - Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer Phase 1/Phase 2
Completed NCT01714219 - Effect of New Posterior Reconstruction Method on Recovery of Continence After Robot-assisted Laparoscopic Prostatectomy N/A
Active, not recruiting NCT03315754 - Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer. Phase 2
Recruiting NCT05010343 - Functional Image-Guided Carbon Ion Irradiation With Simultaneous Integrated Boost for Prostate Cancer Phase 2
Recruiting NCT06325995 - Hypofractionated Post-prostatectomy Radiotherapy (HYPORT)for Localized Prostate Cancer N/A
Recruiting NCT06051942 - PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs N/A
Completed NCT02297386 - [18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer Phase 1
Not yet recruiting NCT06117059 - The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance N/A
Withdrawn NCT04225299 - Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer Phase 3
Recruiting NCT06054867 - PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System N/A
Active, not recruiting NCT02435472 - Active Surveillance Exercise Clinical Trial N/A
Completed NCT00717613 - Psychosocial and Patient Education Needs of Prostate Cancer Patients Selecting Watchful Waiting N/A
Completed NCT02662673 - Evaluation of Focal Treatments of Localized Prostate Cancers With High Intensity Focused Ultrasound Using the Focal One® Device N/A
Recruiting NCT05155046 - 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy Phase 2
Completed NCT01902680 - Phase II Study of Feasibility of Focal Therapy for Prostate Cancer of Good Prognosis With Permanent I125 Localized Implant. Phase 2